1
|
Ferron E, David G, Willem C, Legrand N, Salameh P, Anquetil L, Walencik A, Gendzekhadze K, Gagne K, Retière C. Multifactorial determinants of NK cell repertoire organization: insights into age, sex, KIR genotype, HLA typing, and CMV influence. Front Immunol 2024; 15:1389358. [PMID: 38736873 PMCID: PMC11082329 DOI: 10.3389/fimmu.2024.1389358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2024] [Accepted: 04/12/2024] [Indexed: 05/14/2024] Open
Abstract
Introduction Polymorphisms in the KIR and HLA genes contribute to the diversity of the NK cell repertoire. Extrinsic factors also play a role in modifying this repertoire. The best example is cytomegalovirus, which promotes the expansion of memory-like NK cells. However, the mechanisms governing this phenotypic structure are poorly understood. Furthermore, the influence of age and sex has been understudied. Methods In this study, we examined these parameters in a cohort of 200 healthy volunteer blood donors, focusing on the major inhibitory KIR receptors and CD94/NKG2A, as well as the differentiation marker CD57 and the memory-like population marker NKG2C. Flow cytometry and two joint analyses, unsupervised and semi-supervised, helped define the impact of various intrinsic and extrinsic markers on the phenotypic structure of the NK cell repertoire. Results In the KIR NK cell compartment, the KIR3DL1 gene is crucial, as unexpressed alleles lead to a repertoire dominated by KIR2D interacting only with HLA-C ligands, whereas an expressed KIR3DL1 gene allows for a greater diversity of NK cell subpopulations interacting with all HLA class I ligands. KIR2DL2 subsequently favors the KIR2D NK cell repertoire specific to C1/C2 ligands, whereas its absence promotes the expression of KIR2DL1 specific to the C2 ligand. The C2C2Bw4+ environment, marked by strong -21T motifs, favors the expansion of the NK cell population expressing only CD57, whereas the absence of HLA-A3/A11 ligands favors the population expressing only NKG2A, a population highly represented within the repertoire. The AA KIR genotype favors NK cell populations without KIR and NKG2A receptors, whereas the KIR B+ genotypes favor populations expressing KIR and NKG2A. Interestingly, we showed that women have a repertoire enriched in CD57- NK cell populations, while men have more CD57+ NK cell subpopulations. Discussion Overall, our data demonstrate that the phenotypic structure of the NK cell repertoire follows well-defined genetic rules and that immunological history, sex, and age contribute to shaping this NK cell diversity. These elements can contribute to the better selection of hematopoietic stem cell donors and the definition of allogeneic NK cells for cell engineering in NK cell-based immunotherapy approaches.cters are displayed correctly.
Collapse
Affiliation(s)
- Enora Ferron
- Etablissement Français du Sang, Nantes, France
- INSERM UMR1307, CNRS UMR 6075, CRCI2NA, team 12, Nantes, France
- LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France
| | - Gaëlle David
- Etablissement Français du Sang, Nantes, France
- INSERM UMR1307, CNRS UMR 6075, CRCI2NA, team 12, Nantes, France
- LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France
| | - Catherine Willem
- Etablissement Français du Sang, Nantes, France
- INSERM UMR1307, CNRS UMR 6075, CRCI2NA, team 12, Nantes, France
- LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France
| | - Nolwenn Legrand
- Etablissement Français du Sang, Nantes, France
- INSERM UMR1307, CNRS UMR 6075, CRCI2NA, team 12, Nantes, France
- LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France
| | - Perla Salameh
- Etablissement Français du Sang, Nantes, France
- INSERM UMR1307, CNRS UMR 6075, CRCI2NA, team 12, Nantes, France
- LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France
| | - Laetitia Anquetil
- Etablissement Français du Sang, Nantes, France
- Laboratoire d’histocompatibilité de l’Etablissement Français du Sang de Centre-Pays de la Loire, Nantes, France
| | - Alexandre Walencik
- Etablissement Français du Sang, Nantes, France
- Laboratoire d’histocompatibilité de l’Etablissement Français du Sang de Centre-Pays de la Loire, Nantes, France
| | - Ketevan Gendzekhadze
- Department of Hematology and Hematopoietic Stem cell Transplantation (HCT), Human Leukocyte Antigen (HLA) Laboratory, City of Hope, Medical Center, Duarte, CA, United States
| | - Katia Gagne
- Etablissement Français du Sang, Nantes, France
- INSERM UMR1307, CNRS UMR 6075, CRCI2NA, team 12, Nantes, France
- LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France
- LabEx Transplantex, Université de Strasbourg, Strasbourg, France
| | - Christelle Retière
- Etablissement Français du Sang, Nantes, France
- INSERM UMR1307, CNRS UMR 6075, CRCI2NA, team 12, Nantes, France
- LabEx IGO “Immunotherapy, Graft, Oncology”, Nantes, France
| |
Collapse
|
2
|
Nersesian S, Carter EB, Lee SN, Westhaver LP, Boudreau JE. Killer instincts: natural killer cells as multifactorial cancer immunotherapy. Front Immunol 2023; 14:1269614. [PMID: 38090565 PMCID: PMC10715270 DOI: 10.3389/fimmu.2023.1269614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2023] [Accepted: 10/30/2023] [Indexed: 12/18/2023] Open
Abstract
Natural killer (NK) cells integrate heterogeneous signals for activation and inhibition using germline-encoded receptors. These receptors are stochastically co-expressed, and their concurrent engagement and signaling can adjust the sensitivity of individual cells to putative targets. Against cancers, which mutate and evolve under therapeutic and immunologic pressure, the diversity for recognition provided by NK cells may be key to comprehensive cancer control. NK cells are already being trialled as adoptive cell therapy and targets for immunotherapeutic agents. However, strategies to leverage their naturally occurring diversity and agility have not yet been developed. In this review, we discuss the receptors and signaling pathways through which signals for activation or inhibition are generated in NK cells, focusing on their roles in cancer and potential as targets for immunotherapies. Finally, we consider the impacts of receptor co-expression and the potential to engage multiple pathways of NK cell reactivity to maximize the scope and strength of antitumor activities.
Collapse
Affiliation(s)
- Sarah Nersesian
- Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada
| | - Emily B. Carter
- Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada
| | - Stacey N. Lee
- Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada
| | | | - Jeanette E. Boudreau
- Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada
- Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada
- Department of Pathology, Dalhousie University, Halifax, NS, Canada
| |
Collapse
|
3
|
Choi H, Baek IC, Park SA, Park JS, Jeun SS, Kim TG, Ahn S. Polymorphisms of Killer Ig-like Receptors and the Risk of Glioblastoma. J Clin Med 2023; 12:4780. [PMID: 37510895 PMCID: PMC10380963 DOI: 10.3390/jcm12144780] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2023] [Revised: 07/08/2023] [Accepted: 07/18/2023] [Indexed: 07/30/2023] Open
Abstract
PURPOSE The immune responses of natural killer (NK) cells against cancer cells vary by patient. Killer Ig-like receptors (KIRs), which are some of the major receptors involved in regulating NK cell activity for killing cancer cells, have significant genetic variation. Numerous studies have suggested a potential association between the genetic variation of KIR genes and the risk of development or prognosis of various cancer types. However, an association between genetic variations of KIR genes and glioblastoma (GB) remains uncertain. We sought to evaluate the association of genetic variations of KIRs and their ligand genes with the risk of GB development in Koreans. METHODS A case-control study was performed to identify the odds ratios (ORs) of KIR genes and Classes A, B, and, C of the human leukocyte antigen (HLA) for GB. The GB group was comprised of 77 patients with newly diagnosed IDH-wildtype GB at our institution, and the control group consisted of 200 healthy Korean volunteers. RESULTS There was no significant difference in the frequency of KIR genes and KIR haplotypes between the GB and control groups. Genetic variations of KIR-2DL1, 3DL1, and 3DS1 with their ligand genes (HLA-C2, HLA-Bw4/6, and Bw4, respectively) had effects on the risk of GB in Korean patients. The frequency of KIR-2DL1 with HLA-C2 (OR 2.05, CI 1.19-3.52, p = 0.009), the frequency of KIR-3DL1 without HLA-Bw4 (80I) (OR 8.36, CI 4.06-17.18, p < 0.001), and the frequency of KIR-3DL1 with Bw6 (OR 4.54, CI 2.55-8.09, p < 0.001) in the GB group were higher than in the control group. In addition, the frequency of KIR-2DL1 without HLA-C2 (OR 0.44, CI 0.26-0.75, p = 0.003), the frequency of KIR-3DL1 with HLA-Bw4 (80T) (OR 0.13, CI 0.06-0.27, p < 0.001), the frequency of KIR-3DL1 without Bw6 (OR 0.27, CI 0.15-0.49, p < 0.001), and the frequency of KIR-3DS1 with Bw4 (80I) (OR 0.03, CI 0.00-0.50, p < 0.001) in the GB group were lower than in the control group. CONCLUSIONS This study suggests that genetic variations of KIRs and their ligand genes may affect GB development in the Korean population. Further investigations are needed to demonstrate the different immune responses for GB cells according to genetic variations of KIR genes and their ligand genes.
Collapse
Affiliation(s)
- Haeyoun Choi
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
- Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - In-Cheol Baek
- Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Soon A Park
- Department of Biomedicine and Health Sciences, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Jae-Sung Park
- Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Sin-Soo Jeun
- Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Tai-Gyu Kim
- Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
- Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| | - Stephen Ahn
- Department of Neurosurgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
| |
Collapse
|
4
|
David G, Willem C, Legrand N, Djaoud Z, Mérieau P, Walencik A, Guillaume T, Gagne K, Chevallier P, Retière C. Deciphering the biology of KIR2DL3 + T lymphocytes that are associated to relapse in haploidentical HSCT. Sci Rep 2021; 11:15782. [PMID: 34349169 PMCID: PMC8338934 DOI: 10.1038/s41598-021-95245-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Accepted: 07/15/2021] [Indexed: 12/31/2022] Open
Abstract
KIR are mainly expressed on NK cells and to a lesser extent on T lymphocytes. Although the KIR NK cell repertoire was well explored in haploidentical Hematopoietic Stem Cell Transplantation (HSCT), KIR T cell compartment remains to be investigated in this context. In this study, the investigation of NK receptors on T lymphocytes during immune reconstitution after T-cell-replete haploidentical HSCT with Post-Transplant Cyclophosphamide (PTCy) has shown a significant increase of KIR2DL2/3+ T cell frequency at day 25. This was especially observed at day 30 in recipients who relapsed. IL-15 but not IL-12 increased in vitro KIR+ T cell expansion suggesting that the raised IL-15 serum concentration observed after PTCy in haploidentical HSCT might increase KIR+ T cell frequency. Moreover, investigations from healthy blood donors showed a higher inhibiting effect of KIR2DL3 on CMV specific T cell response against allogeneic than autologous C1+ target cells. The association of KIR+ T cell subset with relapse may suggest that inhibitory KIR2DL2/3 limit anti-leukemic effect of specific T lymphocytes at this early step of immune reconstitution. Further phenotypic and mechanistic investigations on this cell subset from a broader cohort of HSCT recipients should clarify its potential implication in relapse occurrence. Our results demonstrate that KIR-HLA interactions known to modulate NK cell functions also modulate T cell immune responses in the context of allogeneic HSCT.
Collapse
Affiliation(s)
- Gaëlle David
- Etablissement Français du Sang-Pays de la Loire, Blood Bank, 34 boulevard Jean Monnet, 44011, Nantes Cedex 01, France
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, 44000, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", 44000, Nantes, France
| | - Catherine Willem
- Etablissement Français du Sang-Pays de la Loire, Blood Bank, 34 boulevard Jean Monnet, 44011, Nantes Cedex 01, France
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, 44000, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", 44000, Nantes, France
| | - Nolwenn Legrand
- Etablissement Français du Sang-Pays de la Loire, Blood Bank, 34 boulevard Jean Monnet, 44011, Nantes Cedex 01, France
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, 44000, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", 44000, Nantes, France
| | - Zakia Djaoud
- Etablissement Français du Sang-Pays de la Loire, Blood Bank, 34 boulevard Jean Monnet, 44011, Nantes Cedex 01, France
| | - Pierre Mérieau
- Etablissement Français du Sang-Pays de la Loire, Blood Bank, 34 boulevard Jean Monnet, 44011, Nantes Cedex 01, France
| | - Alexandre Walencik
- Etablissement Français du Sang-Pays de la Loire, Blood Bank, 34 boulevard Jean Monnet, 44011, Nantes Cedex 01, France
- LabEx Transplantex, Université de Strasbourg, 67000, Strasbourg, France
| | - Thierry Guillaume
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, 44000, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", 44000, Nantes, France
- Hematology Clinic, CHU, 44000, Nantes, France
| | - Katia Gagne
- Etablissement Français du Sang-Pays de la Loire, Blood Bank, 34 boulevard Jean Monnet, 44011, Nantes Cedex 01, France
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, 44000, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", 44000, Nantes, France
- LabEx Transplantex, Université de Strasbourg, 67000, Strasbourg, France
| | - Patrice Chevallier
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, 44000, Nantes, France
- LabEx IGO "Immunotherapy, Graft, Oncology", 44000, Nantes, France
- Hematology Clinic, CHU, 44000, Nantes, France
| | - Christelle Retière
- Etablissement Français du Sang-Pays de la Loire, Blood Bank, 34 boulevard Jean Monnet, 44011, Nantes Cedex 01, France.
- CRCINA, INSERM, CNRS, Université d'Angers, Université de Nantes, 44000, Nantes, France.
- LabEx IGO "Immunotherapy, Graft, Oncology", 44000, Nantes, France.
| |
Collapse
|
5
|
Relevance of Polymorphic KIR and HLA Class I Genes in NK-Cell-Based Immunotherapies for Adult Leukemic Patients. Cancers (Basel) 2021; 13:cancers13153767. [PMID: 34359667 PMCID: PMC8345033 DOI: 10.3390/cancers13153767] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2021] [Revised: 07/22/2021] [Accepted: 07/23/2021] [Indexed: 11/30/2022] Open
Abstract
Simple Summary Immunotherapies are promising approaches to curing different acute leukemias. Natural killer (NK) cells are lymphocytes that are efficient in the elimination of leukemic cells. NK-cell-based immunotherapies are particularly attractive, but the landscape of the heterogeneity of NK cells must be deciphered. This review provides an overview of the polymorphic KIR and HLA class I genes that modulate the NK cell repertoire and how these markers can improve the outcomes of patients with acute leukemia. A better knowledge of these genetic markers that are linked to NK cell subsets that are efficient against hematological diseases will optimize hematopoietic stem-cell donor selection and NK immunotherapy design. Abstract Since the mid-1990s, the biology and functions of natural killer (NK) cells have been deeply investigated in healthy individuals and in people with diseases. These effector cells play a particularly crucial role after allogeneic hematopoietic stem-cell transplantation (HSCT) through their graft-versus-leukemia (GvL) effect, which is mainly mediated through polymorphic killer-cell immunoglobulin-like receptors (KIRs) and their cognates, HLA class I ligands. In this review, we present how KIRs and HLA class I ligands modulate the structural formation and the functional education of NK cells. In particular, we decipher the current knowledge about the extent of KIR and HLA class I gene polymorphisms, as well as their expression, interaction, and functional impact on the KIR+ NK cell repertoire in a physiological context and in a leukemic context. In addition, we present the impact of NK cell alloreactivity on the outcomes of HSCT in adult patients with acute leukemia, as well as a description of genetic models of KIRs and NK cell reconstitution, with a focus on emergent T-cell-repleted haplo-identical HSCT using cyclosphosphamide post-grafting (haplo-PTCy). Then, we document how the immunogenetics of KIR/HLA and the immunobiology of NK cells could improve the relapse incidence after haplo-PTCy. Ultimately, we review the emerging NK-cell-based immunotherapies for leukemic patients in addition to HSCT.
Collapse
|
6
|
Makanga DR, Jullien M, David G, Legrand N, Willem C, Dubreuil L, Walencik A, Touzeau C, Gastinne T, Tessoulin B, Le Gouill S, Mahé B, Gagne K, Chevallier P, Clemenceau B, Retière C. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response. Oncoimmunology 2021; 10:1936392. [PMID: 34178429 PMCID: PMC8204974 DOI: 10.1080/2162402x.2021.1936392] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The antibody-dependent cellular cytotoxicity (ADCC) effector function of natural killer (NK) cells is one of the known mechanisms of action for rituximab-based anti-cancer immunotherapy. Inhibition of the ADCC function of NK cells through interactions between inhibitory killer cell immunoglobulin-like receptors (KIRs) and HLA class I ligands is associated with resistance of cancers to rituximab. In this study, we deeply investigated the impact of KIR, HLA class I, and CD16 genotypes on rituximab-dependent NK cell responses in both an in vitro cellular model from healthy blood donors and ex vivo rituximab-treated non-Hodgkin lymphoma (NHL) patients. We highlight that an HLA environment with limited KIR ligands is beneficial to promoting a higher frequency of KIR+ NK cells including both educated and uneducated NK cells, two NK cell compartments that demonstrate higher rituximab-dependent degranulation than KIR− NK cells. In contrast, a substantial KIR ligand environment favors a higher frequency of poorly effective KIR− NK cells and numerous functional KIR/HLA inhibitions of educated KIR+ NK cells. These phenomena explain why NHL patients with limited KIR ligands respond better to rituximab. In this HLA environment, CD16 polymorphism appears to have a collateral effect. Furthermore, we show the synergic effect of KIR2DS1, which strongly potentiates NK cell ADCC from C2− blood donors against C2+ target cells. Taken together, these results pave the way for stronger prediction of rituximab responses for NHL patients. HLA class I typing and peripheral blood KIR+ NK cell frequency could be simple and useful markers for predicting rituximab response.
Collapse
Affiliation(s)
- Dhon Roméo Makanga
- Etablissement Français Du Sang, Nantes, Nantes, France.,Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | | | - Gaëlle David
- Etablissement Français Du Sang, Nantes, Nantes, France.,Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Nolwenn Legrand
- Etablissement Français Du Sang, Nantes, Nantes, France.,Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Catherine Willem
- Etablissement Français Du Sang, Nantes, Nantes, France.,Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Léa Dubreuil
- Etablissement Français Du Sang, Nantes, Nantes, France.,Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | | | | | | | | | | | | | - Katia Gagne
- Etablissement Français Du Sang, Nantes, Nantes, France.,Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.,LabEx Transplantex, Université De Strasbourg, Strasbourg, France
| | - Patrice Chevallier
- Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France.,Hematology Clinic, CHU, Nantes, France
| | - Béatrice Clemenceau
- Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| | - Christelle Retière
- Etablissement Français Du Sang, Nantes, Nantes, France.,Université De Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO "Immunotherapy, Graft, Oncology", Nantes, France
| |
Collapse
|
7
|
Abstract
In all human cells, human leukocyte antigen (HLA) class I glycoproteins assemble with a peptide and take it to the cell surface for surveillance by lymphocytes. These include natural killer (NK) cells and γδ T cells of innate immunity and αβ T cells of adaptive immunity. In healthy cells, the presented peptides derive from human proteins, to which lymphocytes are tolerant. In pathogen-infected cells, HLA class I expression is perturbed. Reduced HLA class I expression is detected by KIR and CD94:NKG2A receptors of NK cells. Almost any change in peptide presentation can be detected by αβ CD8+ T cells. In responding to extracellular pathogens, HLA class II glycoproteins, expressed by specialized antigen-presenting cells, present peptides to αβ CD4+ T cells. In comparison to the families of major histocompatibility complex (MHC) class I, MHC class II and αβ T cell receptors, the antigenic specificity of the γδ T cell receptors is incompletely understood.
Collapse
Affiliation(s)
- Zakia Djaoud
- Department of Structural Biology and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA; ,
| | - Peter Parham
- Department of Structural Biology and Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California 94305, USA; ,
| |
Collapse
|
8
|
Legrand N, David G, Rodallec A, Gaultier A, Salmon D, Cesbron A, Wittkop L, Raffi F, Gendzekhadze K, Retière C, Allavena C, Gagne K. Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individuals. Clin Exp Immunol 2021; 204:107-124. [PMID: 33314121 DOI: 10.1111/cei.13562] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 12/07/2020] [Accepted: 12/07/2020] [Indexed: 12/17/2022] Open
Abstract
Natural killer (NK) cell functions are regulated by diverse inhibitory and activating receptors, including killer cell immunoglobulin-like receptors (KIR), which interact with human leukocyte antigen (HLA) class I molecules. Some KIR/HLA genetic combinations were reported associated with spontaneous clearance (SC) of hepatitis C virus (HCV) but with discordant results, possibly reflecting KIR and/or HLA gene polymorphism according to populations. KIR/HLA genetic combinations associated with both an exhaustive NK and T cell repertoire were investigated in a cohort of HIV-HCV co-infected individuals with either SC (n = 68) or chronic infection (CI, n = 163) compared to uninfected blood donors [controls (Ctrl), n = 100]. Multivariate analysis showed that the HLA C2C2 environment was associated with SC only in European HIV-HCV co-infected individuals [odds ratio (OR) = 4·30, 95% confidence interval = 1·57-12·25, P = 0·005]. KIR2D+ NK cell repertoire and potential of degranulation of KIR2DL1/S1+ NK cells were similar in the SC European cohort compared to uninfected individuals. In contrast, decreased frequencies of KIR2DS1+ and KIR2DL2+ NK cells were detected in the CI group of Europeans compared to SC and a decreased frequency of KIR2DL1/S1+ NK cells compared to controls. Regarding T cells, higher frequencies of DNAX accessory molecule-1 (DNAM-1)+ and CD57+ T cells were observed in SC in comparison to controls. Interestingly, SC subjects emphasized increased frequencies of KIR2DL2/L3/S2+ T cells compared to CI subjects. Our study underlines that the C2 environment may activate efficient KIR2DL1+ NK cells in a viral context and maintain a KIR2DL2/L3/S2+ mature T cell response in the absence of KIR2DL2 engagement with its cognate ligands in SC group of HCV-HIV co-infected European patients.
Collapse
Affiliation(s)
- N Legrand
- Etablissement Français du Sang (EFS), Nantes, France.,Université de Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France
| | - G David
- Etablissement Français du Sang (EFS), Nantes, France.,Université de Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France
| | - A Rodallec
- Department of Virology, CHU Nantes Hotel Dieu, Nantes, France
| | - A Gaultier
- Department of Biostatistics, CHU Hotel Dieu, Nantes, France
| | - D Salmon
- AP-HP Department of Infectious Diseases, Université Paris Descartes, Paris, France
| | | | - L Wittkop
- INSERM UMR1219, Université de Bordeaux ISPED, Bordeaux, France
| | - F Raffi
- Department of Infectious Diseases, Nantes, France
| | - K Gendzekhadze
- Division of Hematology and Bone Marrow Transplantation, Duarte, CA, USA
| | - C Retière
- Etablissement Français du Sang (EFS), Nantes, France.,Université de Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO, Nantes, France
| | - C Allavena
- Department of Infectious Diseases, Nantes, France
| | - K Gagne
- Etablissement Français du Sang (EFS), Nantes, France.,Université de Nantes, INSERM U1232 CNRS, CRCINA, Nantes, France.,LabEx IGO, Nantes, France.,LabEx Transplantex, Université de Strasbourg, Strasbourg, France
| |
Collapse
|
9
|
Centromeric KIR AA Individuals Harbor Particular KIR Alleles Conferring Beneficial NK Cell Features with Implications in Haplo-Identical Hematopoietic Stem Cell Transplantation. Cancers (Basel) 2020; 12:cancers12123595. [PMID: 33271841 PMCID: PMC7760878 DOI: 10.3390/cancers12123595] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Revised: 11/25/2020] [Accepted: 11/27/2020] [Indexed: 12/25/2022] Open
Abstract
We have recently shown a broad disparity of Natural Killer (NK) cell responses against leukemia highlighting good and bad responders resting on the Killer cell Immunoglobulin-like Receptors (KIR) and HLA genetics. In this study, we deeply studied KIR2D allele expression, HLA-C recognition and functional effect on NK cells in 108 blood donors in combining high-resolution KIR allele typing and multicolor flow cytometry. The KIR2DL1*003 allotype is associated with centromeric (cen) AA motif and confers the highest NK cell frequency, expression level and strength of KIR/HLA-C interactions compared to the KIR2DL1*002 and KIR2DL1*004 allotypes respectively associated with cenAB and BB motifs. KIR2DL2*001 and *003 allotypes negatively affect the frequency of KIR2DL1+ and KIR2DL3+ NK cells. Altogether, our data suggest that cenAA individuals display more efficient KIR2DL alleles (L1*003 and L3*001) to mount a consistent frequency of KIR2DL+ NK cells and to confer an effective NK cell responsiveness. The transposition of our in vitro observations in the T-replete haplo-identical HSCT context led us to observe that cenAA HSC grafts limit significantly the incidence of relapse in patients with myeloid diseases after T-replete haplo-identical HSCT. As NK cells are crucial in HSCT reconstitution, one could expect that the consideration of KIR2DL1/2/3 allelic polymorphism could help to refine scores used for HSC donor selection.
Collapse
|
10
|
Makanga DR, Da Rin de Lorenzo F, David G, Willem C, Dubreuil L, Legrand N, Guillaume T, Peterlin P, Lebourgeois A, Béné MC, Garnier A, Chevallier P, Gendzekhadze K, Cesbron A, Gagne K, Clemenceau B, Retière C. Genetic and Molecular Basis of Heterogeneous NK Cell Responses against Acute Leukemia. Cancers (Basel) 2020; 12:E1927. [PMID: 32708751 PMCID: PMC7409189 DOI: 10.3390/cancers12071927] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 07/10/2020] [Accepted: 07/13/2020] [Indexed: 02/07/2023] Open
Abstract
Natural killer (NK) cells are key cytotoxic effectors against malignant cells. Polygenic and polymorphic Killer cell Immunoglobulin-like Receptor (KIR) and HLA genes participate in the structural and functional formation of the NK cell repertoire. In this study, we extensively investigated the anti-leukemic potential of NK cell subsets, taking into account these genetic parameters and cytomegalovirus (CMV) status. Hierarchical clustering analysis of NK cell subsets based on NKG2A, KIR, CD57 and NKG2C markers from 68 blood donors identified donor clusters characterized by a specific phenotypic NK cell repertoire linked to a particular immunogenetic KIR and HLA profile and CMV status. On the functional side, acute lymphoblastic leukemia (ALL) was better recognized by NK cells than acute myeloid leukemia (AML). However, a broad inter-individual disparity of NK cell responses exists against the same leukemic target, highlighting bad and good NK responders. The most effective NK cell subsets against different ALLs expressed NKG2A and represented the most frequent subset in the NK cell repertoire. In contrast, minority CD57+ or/and KIR+ NK cell subsets were more efficient against AML. Overall, our data may help to optimize the selection of hematopoietic stem cell donors on the basis of immunogenetic KIR/HLA for ALL patients and identify the best NK cell candidates in immunotherapy for AML.
Collapse
Affiliation(s)
- Dhon Roméo Makanga
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
| | - Francesca Da Rin de Lorenzo
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
| | - Gaëlle David
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
| | - Catherine Willem
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
| | - Léa Dubreuil
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
| | - Nolwenn Legrand
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
| | - Thierry Guillaume
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- Hematology Clinic, CHU, 44000 Nantes, France; (P.P.); (A.L.); (A.G.)
| | - Pierre Peterlin
- Hematology Clinic, CHU, 44000 Nantes, France; (P.P.); (A.L.); (A.G.)
| | | | - Marie Christine Béné
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
- Hematology Biology, CHU, 44000 Nantes, France
| | - Alice Garnier
- Hematology Clinic, CHU, 44000 Nantes, France; (P.P.); (A.L.); (A.G.)
| | - Patrice Chevallier
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
- Hematology Clinic, CHU, 44000 Nantes, France; (P.P.); (A.L.); (A.G.)
| | - Ketevan Gendzekhadze
- HLA Laboratory, Department of Hematology and HCT, City of Hope, Medical Center, Duarte, CA 91010, USA;
| | - Anne Cesbron
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- LabEx Transplantex, Université de Strasbourg, 67000 Strasbourg, France
| | - Katia Gagne
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
- LabEx Transplantex, Université de Strasbourg, 67000 Strasbourg, France
| | - Béatrice Clemenceau
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
| | - Christelle Retière
- Etablissement Français du Sang, 44011 Nantes, France; (D.R.M.); (F.D.R.d.L.); (G.D.); (C.W.); (L.D.); (N.L.); (A.C.); (K.G.)
- Université de Nantes, INSERM U1232 CNRS, CRCINA, F-44000 Nantes, France; (T.G.); (M.C.B.); (P.C.); (B.C.)
- LabEx IGO “Immunotherapy, Graft, Oncology”, F-44000 Nantes, France
| |
Collapse
|
11
|
Fang F, Xiao W, Tian Z. Challenges of NK cell-based immunotherapy in the new era. Front Med 2018; 12:440-450. [PMID: 30047028 DOI: 10.1007/s11684-018-0653-9] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 06/26/2018] [Indexed: 12/20/2022]
Abstract
Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells (PBMCs), stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.
Collapse
Affiliation(s)
- Fang Fang
- Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, 230027, China
- Hefei National Laboratory for Physical Sciences at Microscale, Hefei, 230027, China
| | - Weihua Xiao
- Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, 230027, China.
- Hefei National Laboratory for Physical Sciences at Microscale, Hefei, 230027, China.
| | - Zhigang Tian
- Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei, 230027, China.
- Hefei National Laboratory for Physical Sciences at Microscale, Hefei, 230027, China.
| |
Collapse
|
12
|
Mack SJ, Udell J, Cohen F, Osoegawa K, Hawbecker SK, Noonan DA, Ladner MB, Goodridge D, Trachtenberg EA, Oksenberg JR, Erlich HA. High resolution HLA analysis reveals independent class I haplotypes and amino-acid motifs protective for multiple sclerosis. Genes Immun 2018; 20:308-326. [PMID: 29307888 PMCID: PMC6035897 DOI: 10.1038/s41435-017-0006-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2017] [Revised: 07/31/2017] [Accepted: 08/11/2017] [Indexed: 11/24/2022]
Abstract
We investigated association between HLA class I and class II alleles and haplotypes, and KIR loci and their HLA class I ligands, with multiple sclerosis (MS) in 412 European-American MS patients and 419 ethnically-matched controls, using next generation sequencing. The DRB1*15:01~DQB1*06:02 haplotype was highly predisposing (odds ratio (OR) = 3.98; 95% confidence interval (CI) = 3−5.31; p-value (p) = 2.22E−16), as was DRB1*03:01~DQB1*02:01 (OR = 1.63; CI = 1.19–2.24; p = 1.41E−03). Hardy-Weinberg (HW) analysis in MS patients revealed a significant DRB1*03:01~DQB1*02:01 homozyote excess (15 observed, 8.6 expected; p = 0.016). The OR for this genotype (5.27; CI = 1.47–28.52; p = 0.0036) suggests a recessive MS risk model. Controls displayed no HW deviations. The C*03:04~B*40:01 haplotype (OR = 0.27; CI = 0.14–0.51; p = 6.76E−06) was highly protective for MS, especially in haplotypes with A*02:01 (OR = 0.15; CI = 0.04–0.45; p = 6.51E−05). By itself, A*02:01 is moderately protective, (OR = 0.69; CI = 0.54–0.87; p = 1.46E−03), and haplotypes of A*02:01 with the HLA-B Thr80 Bw4 variant (Bw4T) more so (OR = 0.53; CI = 0.35–0.78; p = 7.55E−04). Protective associations with the Bw4 KIR ligand resulted from linkage disequilibrium (LD) with DRB1*15:01, but the Bw4T variant was protective (OR = 0.64; CI = 0.49–0.82; p = 3.37E−04) independent of LD with DRB1*15:01. The Bw4I variant was not associated with MS. Overall, we find specific class I HLA polymorphisms to be protective for MS, independent of the strong predisposition conferred by DRB1*15:01.
Collapse
Affiliation(s)
- Steven J Mack
- Center for Genetics, Children's Hospital Oakland Research Institute, Oakland, CA, USA.
| | - Julia Udell
- University of Minnesota Twin Cities, Minneapolis, MN, USA
| | - Franziska Cohen
- Center for Genetics, Children's Hospital Oakland Research Institute, Oakland, CA, USA
| | - Kazutoyo Osoegawa
- Histocompatibility, Immunogenetics & Disease Profiling Laboratory, Stanford Blood Center, Palo Alto, CA, USA
| | - Sharon K Hawbecker
- Center for Genetics, Children's Hospital Oakland Research Institute, Oakland, CA, USA
| | - David A Noonan
- Center for Genetics, Children's Hospital Oakland Research Institute, Oakland, CA, USA
| | - Martha B Ladner
- Center for Genetics, Children's Hospital Oakland Research Institute, Oakland, CA, USA
| | | | | | - Jorge R Oksenberg
- Department of Neurology, University of California, San Francisco, CA, USA
| | - Henry A Erlich
- Center for Genetics, Children's Hospital Oakland Research Institute, Oakland, CA, USA
| |
Collapse
|
13
|
Impact of Graft-Versus-Graft Natural Killer Cell Alloreactivity on Single Unit Dominance After Double Umbilical Cord Blood Transplantation. Transplantation 2017; 101:2092-2101. [PMID: 27798515 DOI: 10.1097/tp.0000000000001545] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
BACKGROUND Natural killer (NK) cell alloreactivity is favored after double umbilical cord blood transplantation (dUCBT) in which cord blood (UCB) units and patients are often HLA class I mismatched. Generally, only 1 UCB unit persists after dUCBT. We hypothesize, that NK cell alloreactivity mediated by killer cell immunoglobulin-like receptor (KIR)-HLA interactions may explain the dominance of 1UCB unit over the other after dUCBT. METHODS We investigated the impact of KIR NK cell alloreactivities on the dominance of 1 full UCB unit in 50 dUCBT. We analyzed the effects of the KIR/HLA genetic incompatibilities and studied cord blood cells at both the phenotypic and functional levels. RESULTS The genetic combination of KIR3DL1 loser UCB unit/Bw4 winner UCB unit determined both the dominance of 1 UCB unit (hazards ratio, 2.88 [1.32-6.27], P = 0.0077) and correlated with an increased incidence of relapse (hazards ratio, 4.91 [1.39-17.3], P = 0.0134). It is interesting to note that cord blood cells exhibited extremely low HLA class I expression. Moreover, resting cord blood KIR3DL1 NK cells exhibited a basal alloreactivity against Bw4 target cells that increased upon activation, thus triggering death by apoptosis. CONCLUSIONS Our unicentric study suggests, for the first time, the significant impact of KIR NK cell alloreactivity in the determination of which UCB unit will dominate in dUCBT.
Collapse
|
14
|
Fang F, Xiao W, Tian Z. NK cell-based immunotherapy for cancer. Semin Immunol 2017; 31:37-54. [DOI: 10.1016/j.smim.2017.07.009] [Citation(s) in RCA: 156] [Impact Index Per Article: 22.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2017] [Accepted: 07/24/2017] [Indexed: 12/19/2022]
|
15
|
Bernson E, Hallner A, Sander FE, Wilsson O, Werlenius O, Rydström A, Kiffin R, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia. Leukemia 2017; 31:2552-2559. [PMID: 28529313 PMCID: PMC5729331 DOI: 10.1038/leu.2017.151] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2017] [Revised: 05/03/2017] [Accepted: 05/09/2017] [Indexed: 12/23/2022]
Abstract
Interactions between killer-immunoglobulin-like receptors (KIRs) and their HLA class I ligands are instrumental in natural killer (NK) cell regulation and protect normal tissue from NK cell attack. Human KIR haplotypes comprise genes encoding mainly inhibitory receptors (KIR A) or activating and inhibitory receptors (KIR B). A substantial fraction of humans lack ligands for inhibitory KIRs (iKIRs), that is, a ‘missing ligand’ genotype. KIR B/x and missing ligand genotypes may thus give rise to potentially autoreactive, unlicensed NK cells. Little is known regarding the impact of such genotypes in untransplanted acute myeloid leukemia (AML). For this study, NK cell phenotypes and KIR/HLA genotypes were determined in 81 AML patients who received immunotherapy with histamine dihydrochloride and low-dose IL-2 for relapse prevention (NCT01347996). We observed that presence of unlicensed NK cells impacted favorably on clinical outcome, in particular among patients harboring functional NK cells reflected by high expression of the natural cytotoxicity receptor (NCR) NKp46. Genotype analyses suggested that the clinical benefit of high NCR expression was restricted to patients with a missing ligand genotype and/or a KIR B/x genotype. These data imply that functional NK cells are significant anti-leukemic effector cells in patients with KIR/HLA genotypes that favor NK cell autoreactivity.
Collapse
Affiliation(s)
- E Bernson
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - A Hallner
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - F E Sander
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - O Wilsson
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - O Werlenius
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.,Department of Hematology, University of Gothenburg, Gothenburg, Sweden
| | - A Rydström
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - R Kiffin
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - M Brune
- Department of Hematology, University of Gothenburg, Gothenburg, Sweden
| | - R Foà
- Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - J Aurelius
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden.,Department of Hematology, University of Gothenburg, Gothenburg, Sweden
| | - A Martner
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - K Hellstrand
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| | - F B Thorén
- TIMM Laboratory, Sahlgrenska Cancer Center, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|
16
|
van der Ploeg K, Chang C, Ivarsson MA, Moffett A, Wills MR, Trowsdale J. Modulation of Human Leukocyte Antigen-C by Human Cytomegalovirus Stimulates KIR2DS1 Recognition by Natural Killer Cells. Front Immunol 2017; 8:298. [PMID: 28424684 PMCID: PMC5372792 DOI: 10.3389/fimmu.2017.00298] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Accepted: 03/03/2017] [Indexed: 02/02/2023] Open
Abstract
The interaction of inhibitory killer cell Ig-like receptors (KIRs) with human leukocyte antigen (HLA) class I molecules has been characterized in detail. By contrast, activating members of the KIR family, although closely related to inhibitory KIRs, appear to interact weakly, if at all, with HLA class I. KIR2DS1 is the best studied activating KIR and it interacts with C2 group HLA-C (C2-HLA-C) in some assays, but not as strongly as KIR2DL1. We used a mouse 2B4 cell reporter system, which carries NFAT-green fluorescent protein with KIR2DS1 and a modified DAP12 adaptor protein. KIR2DS1 reporter cells were not activated upon coculture with 721.221 cells transfected with different HLA-C molecules, or with interferon-γ stimulated primary dermal fibroblasts. However, KIR2DS1 reporter cells and KIR2DS1+ primary natural killer (NK) cells were activated by C2-HLA-C homozygous human fetal foreskin fibroblasts (HFFFs) but only after infection with specific clones of a clinical strain of human cytomegalovirus (HCMV). Active viral gene expression was required for activation of both cell types. Primary NKG2A-KIR2DS1+ NK cell subsets degranulated after coculture with HCMV-infected HFFFs. The W6/32 antibody to HLA class I blocked the KIR2DS1 reporter cell interaction with its ligand on HCMV-infected HFFFs but did not block interaction with KIR2DL1. This implies a differential recognition of HLA-C by KIR2DL1 and KIR2DS1. The data suggest that modulation of HLA-C by HCMV is required for a potent KIR2DS1-mediated NK cell activation.
Collapse
Affiliation(s)
| | - Chiwen Chang
- Department of Pathology, University of Cambridge, Cambridge, UK
| | | | - Ashley Moffett
- Department of Pathology, University of Cambridge, Cambridge, UK
| | - Mark R. Wills
- Department of Medicine, University of Cambridge, Cambridge, UK,*Correspondence: Mark R. Wills, ; John Trowsdale,
| | - John Trowsdale
- Department of Pathology, University of Cambridge, Cambridge, UK,*Correspondence: Mark R. Wills, ; John Trowsdale,
| |
Collapse
|
17
|
Pradier A, Simonetta F, Waldvogel S, Bosshard C, Tiercy JM, Roosnek E. Modulation of T-bet and Eomes during Maturation of Peripheral Blood NK Cells Does Not Depend on Licensing/Educating KIR. Front Immunol 2016; 7:299. [PMID: 27605928 PMCID: PMC4995208 DOI: 10.3389/fimmu.2016.00299] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 07/25/2016] [Indexed: 12/11/2022] Open
Abstract
Peripheral natural killer (NK) cells upregulate T-bet and downregulate Eomes, the key transcription factors regulating NK cell maturation and function during the last maturation steps toward terminally differentiated effector cells. During this process, NK cells acquire killer immunoglobulin-like receptors (KIR) and effector functions, such as cytotoxicity and target cell-induced cytokine production. Inhibitory KIR are pivotal in the control of effector functions, but whether they also modulate T-bet/Eomes expression is unknown. We have measured T-bet/Eomes levels, KIR expression, and effector functions of maturing CD94negCD56dimNK cells using CD57 as surface marker for maturation. Our cohort consisted of 23 healthy blood donors (HBD) homozygous for the KIR A haplotype that contains only inhibitory KIR2DL1 (ligand HLA-C2), KIR2DL3 (ligand HLA-C1), and KIR3DL1 (ligand HLA-Bw4). We confirm that during maturation of NK cells, the number of KIR increases, levels of T-bet/Eomes are modulated, and that cells acquire effector functions, such as cytotoxicity (CD107) and target cell-induced cytokine production (TNF-α). Because maturation was associated with the increase of the number of KIR as well as with the modulation of T-bet/Eomes, the number of KIR correlated with the extent of T-bet/Eomes modulation. However, whether the KIR were triggered by their cognate HLA ligands or not had no impact on T-bet and Eomes expression, indicating that modulation of T-box transcription factors during NK cell maturation does not depend on signals conveyed by KIR. We discuss the relevance of this finding in the context of models of NK cell maturation while cautioning that results obtained in a perhaps quite heterogeneous cohort of HBD are not necessarily conclusive.
Collapse
Affiliation(s)
- Amandine Pradier
- Division of Hematology, Department of Medical Specialties, Geneva University Hospitals, University of Geneva , Geneva , Switzerland
| | - Federico Simonetta
- Division of Hematology, Department of Medical Specialties, Geneva University Hospitals, University of Geneva , Geneva , Switzerland
| | - Sophie Waldvogel
- Division of Hematology, Department of Medical Specialties, Geneva University Hospitals, University of Geneva , Geneva , Switzerland
| | - Carine Bosshard
- Division of Hematology, Department of Medical Specialties, Geneva University Hospitals, University of Geneva , Geneva , Switzerland
| | - Jean-Marie Tiercy
- Transplantation Immunology Unit, National Reference Laboratory for Histocompatibility, Department of Genetics and Laboratory Medicine, University Hospital Geneva , Geneva , Switzerland
| | - Eddy Roosnek
- Division of Hematology, Department of Medical Specialties, Geneva University Hospitals, University of Geneva , Geneva , Switzerland
| |
Collapse
|
18
|
Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI). Bone Marrow Transplant 2016; 51:1499-1503. [PMID: 27272444 DOI: 10.1038/bmt.2016.151] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
19
|
Donor KIR B Genotype Improves Progression-Free Survival of Non-Hodgkin Lymphoma Patients Receiving Unrelated Donor Transplantation. Biol Blood Marrow Transplant 2016; 22:1602-1607. [PMID: 27220262 DOI: 10.1016/j.bbmt.2016.05.016] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2016] [Accepted: 05/13/2016] [Indexed: 11/20/2022]
Abstract
Donor killer immunoglobulin-like receptor (KIR) genotypes are associated with relapse protection and survival after allotransplantation for acute myelogenous leukemia. We examined the possibility of a similar effect in a cohort of 614 non-Hodgkin lymphoma (NHL) patients receiving unrelated donor (URD) T cell-replete marrow or peripheral blood grafts. Sixty-four percent (n = 396) of donor-recipient pairs were 10/10 allele HLA matched and 26% were 9/10 allele matched. Seventy percent of donors had KIR B/x genotype; the others had KIR A/A genotype. NHL patients receiving 10/10 HLA-matched URD grafts with KIR B/x donors experienced significantly lower relapse at 5 years (26%; 95% confidence interval [CI], 21% to 32% versus 37%; 95% CI, 27% to 46%; P = .05) compared with KIR A/A donors, resulting in improved 5-year progression-free survival (PFS) (35%; 95% CI, 26% to 44% versus 22%; 95% CI, 11% to 35%; P = .007). In multivariate analysis, use of KIR B/x donors was associated with significantly reduced relapse risk (relative risk [RR], .63, P = .02) and improved PFS (RR, .71, P = .008). The relapse protection afforded by KIR B/x donors was not observed in HLA-mismatched transplantations and was not specific to any particular KIR-B gene. Selecting 10/10 HLA-matched and KIR B/x donors should benefit patients with NHL receiving URD allogeneic transplantation.
Collapse
|
20
|
Rettman P, Willem C, David G, Riou R, Legrand N, Esbelin J, Cesbron A, Senitzer D, Gagne K, Retière C. New insights on the natural killer cell repertoire from a thorough analysis of cord blood cells. J Leukoc Biol 2016; 100:471-9. [DOI: 10.1189/jlb.1hi0116-036r] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Accepted: 03/10/2016] [Indexed: 11/24/2022] Open
|
21
|
Hens J, Jennes W, Kestens L. The role of NK cells in HIV-1 protection: autologous, allogeneic or both? AIDS Res Ther 2016; 13:15. [PMID: 26997965 PMCID: PMC4799629 DOI: 10.1186/s12981-016-0099-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Accepted: 03/09/2016] [Indexed: 12/03/2022] Open
Abstract
Natural killer (NK) cells specialize in killing virally infected- or tumor cells and are part of the innate immune system. The activational state of NK cells is determined by the balance of incoming activating and inhibitory signals mediated by receptor-ligand binding with the target cell. These receptor-ligand bonds mainly consist of the killer immunoglobulin-like receptors (KIR), which are expressed at the cell surface of NK cells, and their ligands: the highly variable human leukocyte antigen -class I molecules (HLA). Absence of an inhibitory receptor-ligand bond lowers the NK cell activation threshold, whereas an activating receptor-ligand bond stimulates the cell, potentially overcoming this threshold and triggering NK cell activation. NK cells influence the course of infection as well as the acquisition of HIV-1. Several lines of evidence relate the activating NK cell receptor KIR3DS1, in the presence or absence of its putative ligand HLA-Bw4, with slower disease progression as well as resistance to HIV-1 infection. Overall, resistance to HIV-1 infection predominantly correlates with activating KIR/HLA profiles, consisting of e.g. activating KIRs, group B haplotypes, or inhibitory KIRs in absence of their ligands. Such a conclusion is less evident for studies of HIV-1 disease progression, with studies reporting beneficial as well as detrimental effects of activating KIR/HLA genotypes. It is likely that KIR/HLA association studies are complicated by the complexity of the KIR and HLA loci and their mutual interactions, as well as by additional factors like route of HIV exposure, immune activation, presence of co-infections, and the effect of anti-HIV-1 antibodies. One newly discovered NK cell activation pathway associated with resistance to HIV-1 infection involves the presence of an iKIR/HLA mismatch between partners. The absence of such an iKIR/HLA bond renders donor-derived allogeneic HIV-1 infected cells vulnerable to NK cell responses during HIV-1 transmission. Therefore, theoretically, HIV-1 would be eliminated before it has the chance to infect the autologous cells in the recipient. While this “alloreactive” NK cell mechanism is especially relevant to HIV transmission in monogamous couples, it would be interesting to investigate how it could influence resistance to HIV in other settings. The objective of this review is to summarize the knowledge about these autologous and alloreactive NK cell responses with regard to HIV-1 outcome.
Collapse
|
22
|
Dambaeva SV, Lee DH, Sung N, Chen CY, Bao S, Gilman-Sachs A, Kwak-Kim J, Beaman KD. Recurrent Pregnancy Loss in Women with Killer Cell Immunoglobulin-Like Receptor KIR2DS1 is Associated with an Increased HLA-C2 Allelic Frequency. Am J Reprod Immunol 2015; 75:94-103. [PMID: 26589762 DOI: 10.1111/aji.12453] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 10/20/2015] [Indexed: 02/06/2023] Open
Abstract
PROBLEM During human pregnancy, the uterine lining is highly populated with killer-immunoglobulin-like receptor (KIR)-expressing NK cells that recognize HLA-C molecules on trophoblast cells. The goal of this study was to analyze the KIR gene contents and frequencies in a N. American cohort of women with RPL of unknown etiology to evaluate whether there is a genetic susceptibility to RPL based on a woman's KIR repertoire and her HLA-C group, as well as the HLA-C group of the partner. METHOD OF STUDY The frequencies of KIR and HLA-C1 and HLA-C2 genes were evaluated in 139 Caucasian women with RPL; HLA-C1, and HLA-C2 group genes were analyzed in their partners (n = 42). The gene frequencies were compared with data reported from corresponding populations. RESULTS Overall, the frequencies of HLA-C groups and KIR genes and genotypes in RPL cohort resembled the frequencies for US Caucasians. The HLA-C1 and HLA-C2 group distribution was significantly different between women with or without KIR2DS1. Women positive for KIR2DS1 (45.3% of the study cohort) had an increased frequency of its ligand, HLA-C2 (0.5159 versus 0.3684 in KIR2DS1 negative women, P = 0.014). CONCLUSION Our results indicate that among KIR2DS1 pos women, the co-expression of HLA-C2 is associated with RPL.
Collapse
Affiliation(s)
- Svetlana V Dambaeva
- Clinical Immunology Laboratory, Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Dong Hyung Lee
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Nayoung Sung
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Chi-Yao Chen
- Clinical Immunology Laboratory, Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Shihua Bao
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Alice Gilman-Sachs
- Clinical Immunology Laboratory, Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Joanne Kwak-Kim
- Reproductive Medicine Center, Department of Obstetrics and Gynecology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| | - Kenneth D Beaman
- Clinical Immunology Laboratory, Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
| |
Collapse
|
23
|
Roquilly A, David G, Cinotti R, Vourc'h M, Morin H, Rozec B, Retière C, Asehnoune K. Role of IL-12 in overcoming the low responsiveness of NK cells to missing self after traumatic brain injury. Clin Immunol 2015; 177:87-94. [PMID: 26387630 DOI: 10.1016/j.clim.2015.08.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 08/07/2015] [Accepted: 08/18/2015] [Indexed: 01/13/2023]
Abstract
Blood samples from 32 patients with severe Traumatic brain injury (TBI) were studied and compared with 11 cardiac surgery patients, and 29 healthy controls. A dramatic decreased expression of HLA class I molecules on monocytes was associated with increased KIR+ NK cell frequency in TBI patients. Overall, the phenotype of TBI NK cells marked by KIR and CD57 expression and lower level of NKp46 and DNAM-1 reflected a differentiated state. The NK-cell response to missing self was marked by lower degranulation and lower IFN-γ production after stimulation with HLA class I deficient cell line. In contrast, the NK-cell ADCC was not altered. IL-12 was able to restore both IFN-γ production and the cytotoxicity capacities of NK cells. This study provides the first extensive description of the phenotype and functions of NK cells in TBI patients. Further evaluation of IL-12 treatment to overcome immunosuppression-induced nosocomial infections is warranted.
Collapse
Affiliation(s)
- Antoine Roquilly
- Intensive Care Unit, Anesthesia and Critical Care Department, Hôtel Dieu - HME, University Hospital of Nantes, France
| | - Gaëlle David
- Intensive Care Unit, Anesthesia and Critical Care Department, Hôtel Dieu - HME, University Hospital of Nantes, France; Université de Nantes, Faculté de Médecine, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826 Nantes, France; Etablissement Français du Sang, Nantes, France; Equipe d'Accueil 4271, ImmunoVirologie et Polymorphisme Génétique, Université de Nantes, France
| | - Raphael Cinotti
- Intensive Care Unit, Anesthesia and Critical Care Department, Hôtel Dieu - HME, University Hospital of Nantes, France; Université de Nantes, Faculté de Médecine, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826 Nantes, France
| | - Mickaël Vourc'h
- Intensive Care Unit, Anesthesia and Critical Care Department, Hôtel Dieu - HME, University Hospital of Nantes, France; Université de Nantes, Faculté de Médecine, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826 Nantes, France
| | - Helene Morin
- Intensive Care Unit, Anesthesia and Critical Care Department, Laennec, University Hospital of Nantes,Nantes, France
| | - Bertrand Rozec
- Intensive Care Unit, Anesthesia and Critical Care Department, Laennec, University Hospital of Nantes,Nantes, France
| | - Christelle Retière
- Etablissement Français du Sang, Nantes, France; Equipe d'Accueil 4271, ImmunoVirologie et Polymorphisme Génétique, Université de Nantes, France
| | - Karim Asehnoune
- Intensive Care Unit, Anesthesia and Critical Care Department, Hôtel Dieu - HME, University Hospital of Nantes, France; Université de Nantes, Faculté de Médecine, Thérapeutiques Cliniques et Expérimentales des Infections, EA 3826 Nantes, France.
| |
Collapse
|
24
|
Future directions of clinical laboratory evaluation of pregnancy. Cell Mol Immunol 2014; 11:582-8. [PMID: 25042633 DOI: 10.1038/cmi.2014.62] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Revised: 06/16/2014] [Accepted: 06/17/2014] [Indexed: 01/23/2023] Open
Abstract
In recent years, our understanding of how the immune system interacts with the developing fetus and placenta has greatly expanded. There are many laboratories that provide tests for diagnosis of pregnancy outcome in women who have recurrent pregnancy loss (RPL) or pre-eclampsia. These tests are based on the premise that immune response to the fetus is equivalent to the adaptive immune response to a transplant. New understanding leads to the concept that the activated innate response is vital for pregnancy and this can result in more effective testing and treatment to prevent an abnormal pregnancy in the future. We describe here only three such areas for future testing: one area involves sperm and semen and factors necessary for successful fertilization; another area would determine conditions for production of growth factors necessary for implantation in the uterus; finally, the last area would be to determine conditions necessary for the vascularization of the placenta and growing fetus by activated natural killer (NK) cells (combinations of killer cell immunoglobulin-like receptor (KIR) family genes with HLA-C haplotypes) that lead to capability of secreting angiogenic growth factors. These areas are novel but understanding their role in pregnancy can lead to insight into how to maintain and treat pregnancies with complicating factors.
Collapse
|
25
|
Ivarsson MA, Michaëlsson J, Fauriat C. Activating killer cell Ig-like receptors in health and disease. Front Immunol 2014; 5:184. [PMID: 24795726 PMCID: PMC4001058 DOI: 10.3389/fimmu.2014.00184] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2014] [Accepted: 04/07/2014] [Indexed: 01/08/2023] Open
Abstract
Expression of non-rearranged HLA class I-binding receptors characterizes human and mouse NK cells. The postulation of the missing-self hypothesis some 30 years ago triggered the subsequent search and discovery of inhibitory MHC-receptors, both in humans and mice. These receptors have two functions: (i) to control the threshold for NK cell activation, a process termed “licensing” or “education,” and (ii) to inhibit NK cell activation during interactions with healthy HLA class I-expressing cells. The discovery of activating forms of KIRs (aKIR) challenged the concept of NK cell tolerance in steady state, as well as during immune challenge: what is the biological role of the activating KIR, in particular when NK cells express aKIRs in the absence of inhibitory receptors? Recently it was shown that aKIRs also participate in the education of NK cells. However, instead of lowering the threshold of activation like iKIRs, the expression of aKIRs has the opposite effect, i.e., rendering NK cells hyporesponsive. These findings may have consequences during NK cell response to viral infection, in cancer development, and in the initial stages of pregnancy. Here we review the current knowledge of activating KIRs, including the biological concept of aKIR-dependent NK cell education, and their impact in health and disease.
Collapse
Affiliation(s)
- Martin A Ivarsson
- Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge , Stockholm , Sweden
| | - Jakob Michaëlsson
- Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge , Stockholm , Sweden
| | - Cyril Fauriat
- U1068, CRCM, Immunity and Cancer, INSERM , Marseille , France ; Institut Paoli-Calmettes , Marseille , France ; UM 105, Aix-Marseille Université , Marseille , France ; UMR 7258, CNRS , Marseille , France ; U1068, CRCM, Plateforme d'Immunomonitoring en Cancérologie, INSERM , Marseille , France
| |
Collapse
|
26
|
David G, Djaoud Z, Willem C, Legrand N, Rettman P, Gagne K, Cesbron A, Retière C. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. THE JOURNAL OF IMMUNOLOGY 2013; 191:4778-88. [PMID: 24078689 DOI: 10.4049/jimmunol.1301580] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The interactions of killer Ig-like receptor 2D (KIR2D) with HLA-C ligands contribute to functional NK cell education and regulate NK cell functions. Although simple alloreactive rules have been established for inhibitory KIR2DL, those governing activating KIR2DS function are still undefined, and those governing the formation of the KIR2D repertoire are still debated. In this study, we investigated the specificity of KIR2DL1/2/3 and KIR2DS1/2, dissected each KIR2D function, and assessed the impact of revisited specificities on the KIR2D NK cell repertoire formation from a large cohort of 159 KIR and HLA genotyped individuals. We report that KIR2DL2(+) and KIR2DL3(+) NK cells reacted similarly against HLA-C(+) target cells, irrespective of C1 or C2 allele expression. In contrast, KIR2DL1(+) NK cells specifically reacted against C2 alleles, suggesting a larger spectrum of HLA-C recognition by KIR2DL2 and KIR2DL3 than KIR2DL1. KIR2DS2(+) KIR2DL2(-) NK cell clones were C1-reactive irrespective of their HLA-C environment. However, when KIR2DS2 and KIR2DL2 were coexpressed, NK cell inhibition via KIR2DL2 overrode NK cell activation via KIR2DS2. In contrast, KIR2DL1 and KIR2DS2 had an additive enhancing effect on NK cell responses against C1C1 target cells. KIR2DL2/3/S2 NK cells predominated within the KIR repertoire in KIR2DL2/S2(+) individuals. In contrast, the KIR2DL1/S1 NK cell compartment is dominant in C2C2 KIR2DL2/S2(-) individuals. Moreover, our results suggest that together with KIR2DL2, activating KIR2DS1 and KIR2DS2 expression limits KIR2DL1 acquisition on NK cells. Altogether, our results suggest that the NK cell repertoire is remolded by the activating and inhibitory KIR2D and their cognate ligands.
Collapse
Affiliation(s)
- Gaëlle David
- EA4271 - "ImmunoVirologie et Polymorphisme Génétique", Etablissement Français du Sang/Pays de la Loire, Université de Nantes, 44011 Nantes Cedex 01, France
| | | | | | | | | | | | | | | |
Collapse
|
27
|
Djaoud Z, David G, Bressollette C, Willem C, Rettman P, Gagne K, Legrand N, Mehlal S, Cesbron A, Imbert-Marcille BM, Retière C. Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells. THE JOURNAL OF IMMUNOLOGY 2013; 191:2708-16. [PMID: 23918974 DOI: 10.4049/jimmunol.1301138] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
CMV infection represents a major complication in hematopoietic stem cell transplantation, which compromises graft outcome. Downregulation of HLA class I expression is one mechanism by which CMV evades T cell-mediated immune detection, rendering infected cells vulnerable to killer cell Ig-like receptor (KIR)(+) NK cells. In this study, we observed that the amplified NKG2C(+) NK cell population observed specifically in CMV seropositive individuals mainly expressed KIR2DL receptors. We have shown that HLA class I expression was downregulated on CMV-infected immature dendritic cells (iDCs), which escape to HLA-A2-pp65-specific T lymphocytes but strongly trigger the degranulation of KIR2D(+) NK cells. CMV infection conferred a vulnerability of C2C2(+) iDCs to educated KIR2DL1(+) and KIR2DL3(+) NK cell subsets. Alloreactivity of KIR2DL1(+) NK cell subsets against C1C1(+) iDCs was maintained independently of CMV infection. Unexpectedly, CMV-infected C1C1(+) iDCs did not activate KIR2DL3(+) NK cell reactivity, suggesting a potential CMV evasion to KIR2DL3 NK cell recognition. Altogether, the coexpression of KIR and NKG2C on expanded NK cell subsets could be related to a functional contribution of KIR in CMV infection and should be investigated in hematopoietic stem cell transplantation, in which the beneficial impact of CMV infection has been reported on the graft-versus-leukemia effect.
Collapse
Affiliation(s)
- Zakia Djaoud
- Etablissement Français du Sang-Pays de la Loire, EA4271, Immunovirologie et Polymorphisme Génétique, 44011 Nantes Cedex 01, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Zhang XH, Dai ZX, Zhang GH, Han JB, Zheng YT. Molecular characterization, balancing selection, and genomic organization of the tree shrew (Tupaia belangeri) MHC class I gene. Gene 2013; 522:147-55. [PMID: 23566832 DOI: 10.1016/j.gene.2013.03.113] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Revised: 03/20/2013] [Accepted: 03/25/2013] [Indexed: 10/27/2022]
Abstract
The major histocompatibility complex (MHC) class I genes play a pivotal role in the adaptive immune response among vertebrates. Accordingly, in numerous mammals the genomic structure and molecular characterization of MHC class I genes have been thoroughly investigated. To date, however, little is known about these genes in tree shrews, despite the increasingly popularity of its usage as an animal model. To address this deficiency, we analyzed the structure and characteristic of the tree shrew MHC class I genes (Tube-MHC I) and performed a comparative gene analysis of the tree shrew and other mammal species. We found that the full-length cDNA sequence of the tree shrew MHC class I is 1074bp in length. The deduced peptide is composed of 357 amino acids containing a leader peptide, an α1 and α2 domain, an α3 domain, a transmembrane domain and a cytoplasmic domain. Among these peptides, the cysteines, CD8(+) interaction and N-glycosylation sites are all well conserved. Furthermore, the genomic sequence of the tree shrew MHC class I gene was identified to be 3180bp in length, containing 8 exons and 7 introns. In 21 MHC class I sequences, we conducted an extensive study of nucleotide substitutions. The results indicated that in the peptide binding region (PBR) the rate of non-synonymous substitutions (dN) to synonymous substitutions (dS) was greater than 1, suggesting balancing selection at the PBR. These findings provide valuable contributions in furthering our understanding of the structure, molecular polymorphism, and function of the MHC class I genes in tree shrews, further improving their utility as an animal model in biomedical research.
Collapse
Affiliation(s)
- Xi-He Zhang
- Key laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650223, China
| | | | | | | | | |
Collapse
|
29
|
Gagne K, Willem C, Legrand N, Djaoud Z, David G, Rettman P, Bressollette-Bodin C, Senitzer D, Esbelin J, Cesbron-Gautier A, Schneider T, Retière C. Both the nature of KIR3DL1 alleles and the KIR3DL1/S1 allele combination affect the KIR3DL1 NK-cell repertoire in the French population. Eur J Immunol 2013; 43:1085-98. [PMID: 23436464 DOI: 10.1002/eji.201243007] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2012] [Revised: 12/11/2012] [Accepted: 01/25/2013] [Indexed: 02/04/2023]
Abstract
NK-cell functions are regulated by many activating and inhibitory receptors including KIR3DL1. Extensive allelic polymorphism and variability in expression can directly alter NK-cell phenotype and functions. Here we investigated the KIR3DL1(+) NK-cell repertoire, taking into account the allelic KIR3DL1/S1 polymorphism, KIR3DL1 phenotype, and function. All 109 studied individuals possessed at least one KIR3DL1 allele, with weak KIR3DL1*054, or null alleles being frequently present. In KIR3DL1(high/null) individuals, we observed a bimodal distribution of KIR3DL1(+) NK cells identified by a different KIR3DL1 expression level and cell frequency regardless of a similar amount of both KIR3DL1 transcripts, HLA background, or KIR2D expression. However, this bimodal distribution can be explained by a functional selection following a hierarchy of KIR3DL1 receptors. The higher expression of KIR3DL1 observed on cord blood NK cells suggests the expression of the functional KIR3DL1*004 receptors. Thus, the low amplification of KIR3DL1(high) , KIR3DL1*004 NK-cell subsets during development may be due to extensive signaling via these two receptors. Albeit in a nonexclusive manner, individual immunological experience may contribute to shaping the KIR3DL1 NK-cell repertoire. Together, this study provides new insight into the mechanisms regulating the KIR3DL1 NK-cell repertoire.
Collapse
Affiliation(s)
- Katia Gagne
- Etablissement Français du Sang and Université de Nantes, EA4271 Immunovirologie et Polymorphisme Génétique, Nantes, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
The function of natural killer (NK) cells is controlled by several activating and inhibitory receptors, including the family of killer-immunoglobulin-like receptors (KIRs). One distinctive feature of KIRs is the extensive number of various haplotypes generated by the gene content within the KIR gene locus as well as by highly polymorphic members of the KIR gene family, namely KIR3DL1/S1. Within the KIR3DL1/S1 gene locus, KIR3DS1 represents a conserved allelic variant and displays other unique features in comparison to the highly polymorphic KIR3DL1 allele. KIR3DS1 is present in all human populations and belongs to the KIR haplotype group B. KIR3DS1 encodes for an activating receptor featuring the characteristic short cytoplasmic tail and a positively charged residue within the transmembrane domain, which allows recruitment of the ITAM-bearing adaptor molecule DAP12. Although HLA class I molecules are thought to represent natural KIR ligands, and HLA-Bw4 molecules serve as ligands for KIR3DL1, the ligand for KIR3DS1 still needs to be identified. Despite the lack of formal evidence for an interaction of KIR3DS1 with HLA-Bw4-I80 or any other HLA class I subtype to date, a growing number of associations between the presence of KIR3DS1 and the outcome of viral infections have been described. Especially, the potential protective role of KIR3DS1 in combination with HLA-Bw4-I80 in the context of HIV-1 infection has been studied intensively. In addition, a number of recent studies have associated the presence or absence of KIR3DS1 with the occurrence and outcome of some malignancies, autoimmune diseases, and graft-versus-host disease (GVHD). In this review, we summarize the present knowledge regarding the characteristics of KIRD3S1 and discuss its role in various human diseases.
Collapse
Affiliation(s)
- Christian Körner
- Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University Charlestown, MA, USA
| | | |
Collapse
|
31
|
Moroso V, van der Meer A, Tilanus HW, Kazemier G, van der Laan LJW, Metselaar HJ, Joosten I, Kwekkeboom J. Donor and recipient HLA/KIR genotypes do not predict liver transplantation outcome. Transpl Int 2011; 24:932-42. [PMID: 21672051 DOI: 10.1111/j.1432-2277.2011.01286.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Whether or not Natural Killer (NK) cells affect the immune response to solid organ allografts is still controversial. Main determinants of NK-cell activation are specific HLA/killer-cell immunoglobulin-like receptors (KIR) interactions that, in transplantation, may induce NK-cell alloreactivity. So far, in liver transplantation (LTX) donor-versus-recipient alloreactivity has not been investigated; in addition, studies of predicted recipient-versus-donor NK-cell alloreactivity have led to contradicting results. We typed a cohort of LTX donors and recipients for HLA-C/Bw4 and KIRs. We estimated the effect of NK-cell alloreactivity, as predicted by classically used models, in the donor-versus-recipient direction. The results indicate that HLA/KIR mismatches in the donor-versus-recipient direction do not predict graft rejection nor graft or patient survival, suggesting that donor-derived NK cells do not play a major role in LTX outcome. In addition, when considering predicted NK-cell alloreactivity in the reverse direction (recipient-versus-donor), we first confirmed that donor HLA-C genotype was not associated with acute rejection, graft or patient survival and secondly we found that none of the models describing NK-cell alloreactivity could predict LTX outcome. Overall our observations suggest that, in contrast to what is shown in haematopoietic stem cell transplantation, donor-derived NK cells may not contribute in preventing liver graft rejection, and that recipient-versus-donor NK-cell alloreactivity does not predict LTX outcome.
Collapse
Affiliation(s)
- Viviana Moroso
- Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 2011; 117:4284-92. [PMID: 21355085 DOI: 10.1182/blood-2010-10-316125] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
In allogeneic HSCT, NK-cell alloreactivity is determined by the presence in the donor of NK cells expressing inhibitory killer cell Ig-like receptors (KIRs) that recognize HLA class I allotypes present in the donor but lacking in the recipient. Dominant KIR ligands are the C1 and C2 epitopes of HLA-C. All HLA-C allotypes have either the C1 epitope, the ligand for KIR2DL2/L3, or the C2 epitope, the ligand for KIR2DL1/S1. Here, we show that, in alloreactive NK-cell responses, KIR2DS1 expression represents a remarkable advantage as it allows efficient killing of C2/C2 or C1/C2 myelomonocitic dendritic cells (DCs) and T-cell blasts. When DCs or T-cell blasts were derived from C2/C2, Bw4/Bw4 donors, the activating signals delivered by KIR2DS1 could override the inhibition generated by NKG2A or KIR2DL2/L3 expressed on the same NK-cell clone. Furthermore, substantial lysis of C2/C2, Bw4/Bw6 targets was mediated by KIR2DS1(+) NK cells coexpressing KIR3DL1. Importantly, in the case of C1/C2 targets, KIR2DS1(+) NK cells were inhibited by the coexpression of KIR2DL2/L3 but not of NKG2A. Thus, KIR2DS1 expression in HSC donors may substantially increase the size of the alloreactive NK-cell subset leading to an enhanced ability to limit GVHD and improve engrafment.
Collapse
|
33
|
Analyses of HLA-C–specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011; 117:98-107. [DOI: 10.1182/blood-2010-03-273656] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Abstract
To determine the influence of KIR and HLA class I polymorphism on human NK cell repertoires, 32 different clonotypes representing all possible combinations of 4 inhibitory KIR and NKG2A were analyzed by multicolor flow cytometry. In donors homozygous for the common group A KIR haplotype, a significant influence of HLA-C ligands was seen: KIR repertoires were dominated by clonotypes expressing a single KIR for the respective cognate ligand, either the C1-specific KIR2DL3 or C2-specific KIR2DL1. In contrast, in donors possessing the polymorphic group B haplotypes, a similar adaptation to cognate HLA-C was lacking. We suggest that this discrepancy is largely the result of a suppressive effect of the group B–specific KIR2DL2 on the frequency of KIR2DL1+ NK cells. In functional assays, KIR2DL2 not only recognized C1 but also C2 ligands, showing overlapping specificity with KIR2DL1. Moreover, using an NK cell differentiation assay we show sequential acquisition of KIR2DL2 before KIR2DL1 on developing NK cells. Together, these observations are compatible with a ligand-instructed model of NK cell education, in which recognition of HLA class I by an inhibitory receptor (KIR2DL2) suppresses subsequent expression of a second receptor (KIR2DL1) of related specificity. Importantly, the ligand-instructed model fits to the observed KIR repertoires in both broad KIR haplotype groups.
Collapse
|
34
|
Hiby SE, Apps R, Sharkey AM, Farrell LE, Gardner L, Mulder A, Claas FH, Walker JJ, Redman CC, Morgan L, Tower C, Regan L, Moore GE, Carrington M, Moffett A. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010; 120:4102-10. [PMID: 20972337 PMCID: PMC2964995 DOI: 10.1172/jci43998] [Citation(s) in RCA: 355] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2010] [Accepted: 08/25/2010] [Indexed: 11/17/2022] Open
Abstract
Many common disorders of pregnancy are attributed to insufficient invasion of the uterine lining by trophoblast, fetal cells that are the major cell type of the placenta. Interactions between fetal trophoblast and maternal uterine NK (uNK) cells--specifically interactions between HLA-C molecules expressed by the fetal trophoblast cells and killer Ig-like receptors (KIRs) on the maternal uNK cells--influence placentation in human pregnancy. Consistent with this, pregnancies are at increased risk of preeclampsia in mothers homozygous for KIR haplotype A (KIR AA). In this study, we have demonstrated that trophoblast expresses both paternally and maternally inherited HLA-C surface proteins and that maternal KIR AA frequencies are increased in affected pregnancies only when the fetus has more group 2 HLA-C genes (C2) than the mother. These data raise the possibility that there is a deleterious allogeneic effect stemming from paternal C2. We found that this effect also occurred in other pregnancy disorders (fetal growth restriction and recurrent miscarriage), indicating a role early in gestation for these receptor/ligand pairs in the pathogenesis of reproductive failure. Notably, pregnancy disorders were less frequent in mothers that possessed the telomeric end of the KIR B haplotype, which contains activating KIR2DS1. In addition, uNK cells expressed KIR2DS1, which bound specifically to C2+ trophoblast cells. These findings highlight the complexity and central importance of specific combinations of activating KIR and HLA-C in maternal-fetal immune interactions that determine reproductive success.
Collapse
Affiliation(s)
- Susan E. Hiby
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Richard Apps
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Andrew M. Sharkey
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Lydia E. Farrell
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Lucy Gardner
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Arend Mulder
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Frans H. Claas
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - James J. Walker
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Christopher C. Redman
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Linda Morgan
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Clare Tower
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Lesley Regan
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Gudrun E. Moore
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Mary Carrington
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| | - Ashley Moffett
- Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Centre for Trophoblast Research, Cambridge, United Kingdom.
Cancer and Inflammation Program, Laboratory of Experimental Immunology, SAIC-Frederick, NCI-Frederick, Frederick, Maryland, USA.
Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA.
Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands.
Perinatal Research Group, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, United Kingdom.
Genetics of Pre-eclampsia (GOPEC) consortium (
http://www.gopec.org).
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom.
Department of Clinical Chemistry, Institute of Genetics, University of Nottingham, Nottingham, United Kingdom.
Maternal and Fetal Health Research Centre, St. Mary’s Hospital, Manchester, United Kingdom.
Department of Obstetrics and Gynaecology, St. Mary’s Hospital Medical School, London, United Kingdom.
Clinical and Molecular Genetics Unit, Institute of Child Health, University College London, London, United Kingdom
| |
Collapse
|
35
|
Moesta AK, Graef T, Abi-Rached L, Older Aguilar AM, Guethlein LA, Parham P. Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I. THE JOURNAL OF IMMUNOLOGY 2010; 185:4233-7. [PMID: 20802150 DOI: 10.4049/jimmunol.1001951] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Modulation of human NK cell function by killer cell Ig-like receptors (KIR) and MHC class I is dominated by the bipartite interactions of inhibitory lineage III KIR with the C1 and C2 epitopes of HLA-C. In comparison, the ligand specificities and functional contributions of the activating lineage III KIR remain poorly understood. Using a robust, sensitive assay of KIR binding and a representative panel of 95 HLA class I targets, we show that KIR2DS1 binds C2 with ~50% the avidity of KIR2DL1, whereas KIR2DS2, KIR2DS3, and KIR2DS5 have no detectable avidity for C1, C2, or any other HLA class I epitope. In contrast, the chimpanzee has activating C1- and C2-specific lineage III KIR with strong avidity, comparable to those of their paired inhibitory receptors. One variant of chimpanzee Pt-KIR3DS2, the activating C2-specific receptor, has the same avidity for C2 as does inhibitory Pt-KIR3DL4, and a second variant has ~73% the avidity. Chimpanzee Pt-KIR3DS6, the activating C1-specific receptor, has avidity for C1 that is ~70% that of inhibitory Pt-KIR2DL6. In both humans and chimpanzees we observe an evolutionary trend toward reducing the avidity of the activating C1- and C2-specific receptors through selective acquisition of attenuating substitutions. However, the extent of attenuation has been extreme in humans, as exemplified by KIR2DS2, an activating C1-specific receptor that has lost all detectable avidity for HLA class I. Supporting such elimination of activating C1-specific receptors as a uniquely human phenomenon is the presence of a high-avidity activating C1-specific receptor (Gg-KIR2DSa) in gorilla.
Collapse
Affiliation(s)
- Achim K Moesta
- Department of Structural Biology, School of Medicine, Stanford University, Stanford, CA 94305, USA
| | | | | | | | | | | |
Collapse
|
36
|
Current world literature. Curr Opin Oncol 2010; 22:155-61. [PMID: 20147786 DOI: 10.1097/cco.0b013e32833681df] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
37
|
Cognet C, Farnarier C, Gauthier L, Frassati C, André P, Magérus-Chatinet A, Anfossi N, Rieux-Laucat F, Vivier E, Schleinitz N. Expression of the HLA-C2-specific activating killer-cell Ig-like receptor KIR2DS1 on NK and T cells. Clin Immunol 2010; 135:26-32. [PMID: 20093094 DOI: 10.1016/j.clim.2009.12.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2009] [Revised: 12/18/2009] [Accepted: 12/21/2009] [Indexed: 12/21/2022]
Abstract
Killer Ig-like receptors (KIRs) are MHC class I-specific receptors expressed by Natural Killer (NK) and T cell subsets. KIRs either inhibit (KIR-L) or activate (KIR-S) lymphocyte functions. Inhibitory KIR2DL1 and activating KIR2DS1 share ligand specificity for the HLA-C2 group, consistent with their almost identical extracytoplasmic domain. This homology hampered the distinction between KIR2DL1 and KIR2DS1. We report here the characterization of the KIR2DS1(+) subsets among primary human NK and T cells. Regardless of the host HLA-C genotype, around 10% of circulating NK cells expressed KIR2DS1 in absence of KIR2DL1. In HLA-C2 individuals, KIR2DS1 was not able to induce NK cell education (i.e., the acquisition of NK cell competence) nor to interfere with KIR2DL1-induced NK cell education. KIR2DS1 was also present on rare oligoclonal TCRalphabeta(+)CD8alpha(+) and TCRalphabeta(+)CD4(-)CD8(-) subsets. As KIR2DS1 has been associated with autoimmunity and hematopoietic stem cell transplantation, these results pave the way to dissect the function of KIR2DS1 in these clinical conditions.
Collapse
Affiliation(s)
- Céline Cognet
- Centre d'Immunologie de Marseille-Luminy, Université de la Méditerranée, case 906, Campus de Luminy, 13288 Marseille, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1366-75. [PMID: 19822295 DOI: 10.1016/j.bbmt.2009.06.015] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2009] [Accepted: 06/25/2009] [Indexed: 11/21/2022]
Abstract
Given their antileukemic activity, natural killer (NK) cells can alter the outcome of hematopoietic stem cell transplantation (HSCT). The physiologic functions of NK cells are regulated by the interaction of killer immunoglobulin-like receptors (KIR) with specific HLA class I ligands. In the literature, different models based on HLA class I and/or KIR donor (D)/recipient (R) gene disparities are considered as predictors of NK cell alloreactivity. In this retrospective and multicentric French study, we analyzed the clinical impact of the different NK-alloreactivity models in 264 patients who underwent T repleted unrelated HSCT. First, we did not observe that the "KIR ligand-ligand" model had a significant clinical impact on unrelated HSCT outcome, whereas the "missing KIR ligand" model had a significant but limited effect on unrelated HSCT, because only the absence of C1 ligand in patients with myelogenous diseases was associated with a decreased overall survival (OS) (hazard ratio=2.17, P=.005). The "KIR receptor-receptor" and the "KIR receptor-ligand" models seemed the most capable of predicting NK alloreactivity because they had a significant impact on acute graft-versus-host disease (aGVHD) occurrence, OS, and relapse incidence in D/R unrelated pairs. In particular, KIR3DL1 gene mismatches in the GVH direction (D(+)R(-)) and the D KIR3DL1(+)/3DS1(+) and R Bw4(-) combination were respectively correlated with the lowest OS in HLA identical pairs (HR=1.99, P =.02) and the highest incidence of relapse in HLA nonidentical D/R unrelated pairs (HR=4.72, P =.03). Overall, our results suggest a detrimental effect of KIR3DL1(+)/3DS1(+) donor NK cells transplanted into HLA-Bw4(-) patients in the absence of an educational process via KIR3DL1/HLA-Bw4 interactions.
Collapse
|
39
|
David G, Morvan M, Gagne K, Kerdudou N, Willem C, Devys A, Bonneville M, Folléa G, Bignon JD, Retière C. Discrimination between the main activating and inhibitory killer cell immunoglobulin-like receptor positive natural killer cell subsets using newly characterized monoclonal antibodies. Immunology 2009; 128:172-84. [PMID: 19740374 DOI: 10.1111/j.1365-2567.2009.03085.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
Natural killer (NK) cells are key components of the innate anti-viral and anti-tumour immune responses. NK cell function is regulated by the interaction of killer cell immunoglobulin-like receptors (KIR) with human leucocyte antigen (HLA) class I molecules. In this study, we report on the generation of KIR-specific antibodies allowing for discrimination between activating and inhibitory KIR. For this purpose, BALB/c mice were immunized with human KIR2DS2 recombinant protein. The precise specificity of KIR2DS2-specific clones was determined on KIR-transfected BW cells and KIR-genotyped NK cells. When used in combination with EB6 (KIR2DL1/2DS1) or GL183 (KIR2DL2/2DL3/2DS2), two KIR-specific monoclonal antibodies (mAbs), 8C11 (specific for KIR2DL1/2DL2/2DL3/2DS2) and 1F12 (specific for KIR2DL3/2DS2), discriminated activating KIR2DS1 (8C11(-) EB6(+)) from inhibitory KIR2DL1 (8C11(+) GL183(-)) and KIR2DL2 (1F12(-) GL183(+)), while excluding the main HLA-Cw-specific KIR. Using these mAbs, KIR2DS1 was shown to be expressed on the surface of NK cells from all individuals genotyped as KIR2DS1(+) (n = 23). Moreover, KIR2DS1 and KIR2DL1 were independently expressed on NK cells. We also determined the amino acid position recognized by the 8C11 and 1F12 mAbs, which revealed that some KIR2DL1 allele-encoded proteins are not recognized by 8C11. Because most available anti-KIR mAbs recognize both inhibitory and activating forms of KIR, these newly characterized antibodies should help assess the expression of activating and inhibitory KIR and their functional relevance to NK biology.
Collapse
Affiliation(s)
- Gaëlle David
- Etablissement Français du Sang, Université de Nantes, Immunovirologie et polymorphisme génétique, EA4271 Nantes, F-44000 France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2009; 115:1166-74. [PMID: 19903900 DOI: 10.1182/blood-2009-09-245746] [Citation(s) in RCA: 225] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Abstract
Expression of inhibitory killer cell immunoglobulin-like receptors (KIRs) specific for self-major histocompatibility complex (MHC) class I molecules provides an educational signal that generates functional natural killer (NK) cells. However, the effects of activating KIRs specific for self-MHC class I on NK-cell education remain elusive. Here, we provide evidence that the activating receptor KIR2DS1 tunes down the responsiveness of freshly isolated human NK cells to target cell stimulation in donors homozygous for human leukocyte antigen (HLA)-C2, the ligand of KIR2DS1. The tuning was apparent in KIR2DS1(+) NK cells lacking expression of inhibitory KIRs and CD94/NKG2A, as well as in KIR2DS1(+) NK cells coexpressing the inhibitory MHC class I-specific receptors CD94/NKG2A and KIR2DL3, but not KIR2DL1. However, the tuning of responsiveness was restricted to target cell recognition because KIR2DS1(+) NK cells responded well to stimulation with exogenous cytokines. Our results provide the first example of human NK-cell education by an activating KIR and suggest that the education of NK cells via activating KIRs is a mechanism to secure tolerance that complements education via inhibitory KIRs.
Collapse
|
41
|
Morvan M, Willem C, Gagne K, Kerdudou N, David G, Sébille V, Folléa G, Bignon JD, Retière C. Phenotypic and Functional Analyses of KIR3DL1+and KIR3DS1+NK Cell Subsets Demonstrate Differential Regulation by Bw4 Molecules and Induced KIR3DS1 Expression on Stimulated NK Cells. THE JOURNAL OF IMMUNOLOGY 2009; 182:6727-35. [DOI: 10.4049/jimmunol.0900212] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|